Company: CMND
Filing Date: 2025-11-17
Form Type: 424B5
Source: 0001213900-25-111233
Chunk: 30

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-17
Form: 424B5
Chunk 30
---
 pre-funded warrants, unless such pre-funded warrants
holders are utilizing the cashless exercise provision of the pre-funded warrants.

Upon the holder’s exercise
of a pre-funded warrant, we will issue the Common Shares issuable upon exercise of the pre-funded warrant within two trading days
following our receipt of a notice of exercise, provided that payment of the exercise price has been made (unless exercised to the extent
permitted via the “cashless” exercise provision). Prior to the exercise of any pre-funded warrants to purchase Common Shares,
holders of the pre-funded warrants will not have any of the rights of holders of Common Shares purchasable upon exercise, including the
right to vote, except as set forth therein.

The pre-funded warrant holder
will not have the right to exercise any portion of the pre-funded warrants if the holder (together with its affiliates) would beneficially
own in excess of 4.99% of the number of Common Shares outstanding immediately after giving effect to the exercise, as such percentage
ownership is determined in accordance with the terms of the pre-funded warrants. However, any pre-funded warrant holder may increase or
decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective
until 61 days following notice from the holder to us.

Fundamental Transaction.In
the event of a fundamental transaction, as described in the pre-funded warrants and generally including any reorganization, recapitalization
or reclassification of our Common Shares, the sale, transfer or other disposition of all or substantially all of our properties or assets,
our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding Common Shares, or any person
or group becoming the beneficial owner of more than 50% of the voting power represented by our outstanding Common Shares, the holders
of the pre-funded warrants will be entitled to receive upon exercise of the pre-funded warrants the kind and amount of securities, cash
or other property that the holders would have received had they exercised the pre-funded warrants immediately prior to such fundamental
transaction without regard to any limitations on exercised contained in the pre-funded warrants.

Exchange Listing.We
do not intend to apply to list the pre-funded warrants on any securities exchange or other trading system.

<div align='center'>S-14

USE OF PROCEEDS</div>

We estimate that the net proceeds from our issuance and sale of Common
Shares in this offering will be approximately $1.3 million